TORNALATE
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Feb 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORNALATE is an inhaled small-molecule bronchodilator approved in 1992 for respiratory conditions. The exact mechanism of action and indications are not fully specified in available data, but the inhalation solution formulation suggests use in obstructive airway disease. Generic information and pharmacologic class details are unavailable.
LOE Approaching
As LOE approaches, brand team focus will shift to managed decline and potential generic transition support, with reduced headcount requirements.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORNALATE offers limited career growth opportunities due to its LOE-approaching status and minimal linked job postings. Working on this product is best suited for professionals managing mature brand portfolios or supporting generic transition strategies.
Brand ManagerField Sales Representative
Worked on TORNALATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.